Canada’s dementia experts urge caution in the review of aducanumab, a medication for Alzheimer’s disease

Researchers and clinicians from six leading Canadian organizations working in the dementia research and care field, came to the conclusion that aducanumab – the treatment (or disease-modifying therapy) for Alzheimer’s disease (AD) recently approved conditionally by the FDA and undergoing evaluation at Health Canada – requires further testing before approval and widespread use in patients with AD in Canada.

Visit www.ccna-ccnv.ca/aducanumab for all details.